Exploring novel combinations of targeted therapy in the journey of epidermal growth factor receptor-mutant lung cancers

Exploring novel combinations of targeted therapy in the journey of epidermal growth factor receptor-mutant lung cancers

Bibliographic Details
Main Authors:	Veda Devakumar, Nirmal Vivek Raut, Namrata Britto
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Cancer Research, Statistics, and Treatment
Online Access:	http://www.crstonline.com/article.asp?issn=2590-3233;year=2021;volume=4;issue=1;spage=184;epage=185;aulast=

Similar Items

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
by: Alexis B. Cortot, et al.
Published: (2014-09-01)

Immunotherapy in Epidermal Growth Factor Receptor-mutant  Non-small Cell Lung Cancer
by: Xin WANG, et al.
Published: (2019-08-01)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
by: Xiufeng Pang, et al.
Published: (2016-10-01)

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
by: Karam Khaddour, et al.
Published: (2021-06-01)

Cyclooxygenase-2 contributes to mutant epidermal growth factor receptor lung tumorigenesis by promoting an immunosuppressive environment
by: Mun Kyoung Kim, et al.
Published: (2020-01-01)

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
by: William J. Kelly, et al.
Published: (2018-07-01)

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
by: Huang-Chih Chang, et al.
Published: (2017-03-01)

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
by: Bryan A Faller, et al.
Published: (2009-09-01)

Research Progress of Epidermal Growth Factor Receptor and Molecular-Targeted Therapy in Treatment of Non-Small Cell Lung Cancer
by: Xiaoyou Li, et al.
Published: (2014-03-01)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
by: Lijuan Zhang, et al.
Published: (2021-01-01)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
by: Clémentine Bouchez, et al.
Published: (2020-12-01)

The expression of a mutant epidermal growth factor receptor in prostatic tumours
by: Olapade-Olaopa, E. Oluwabunmi
Published: (2000)

Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma
by: Meador, Catherine Belle
Published: (2015)

Acquired Resistance to Targeted Therapy in EGFR-Mutant Lung Adenocarcinoma
by: Nebhan, Caroline Amalia
Published: (2014)

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
by: Siavash Jabbari, et al.
Published: (2011-10-01)

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
by: Toshimitsu Yamaoka, et al.
Published: (2017-11-01)

Developing Novel Leading Compounds Targeting on Epidermal Growth Factor Receptor in Lung Adenocarcinoma: Curcumin as the Versatile Adjuvant for Gefitinib Therapy
by: Jen-Yi Lee, et al.
Published: (2012)

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
by: Emma-Anne Karlsen, et al.
Published: (2021-05-01)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M
by: Shigeru Kawabata, et al.
Published: (2014-06-01)

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
by: Shouzheng Wang, et al.
Published: (2021-10-01)

Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted Cancer Therapy
by: Tao Wang, et al.
Published: (2019-09-01)

Translational Research on Epidermal Growth Factor Receptor Gene Mutations in Targeted Therapy for Patients with Advanced Non-Small Cell Lung Cancer
by: Xiao-yan WANG, et al.
Published: (2015-12-01)

The Role of Epidermal Growth Factor Receptor in Cancer and their Application for New Targeted Cancer Therapy
by: Farajolah Maleki, et al.
Published: (2018-06-01)

Targeting mutant estrogen receptors
by: Suzanne E Wardell, et al.
Published: (2019-01-01)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
by: Ruofei Yu, et al.
Published: (2021-09-01)

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting
by: Yunha Nam, et al.
Published: (2021-03-01)

Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
by: Sun S, et al.
Published: (2017-04-01)

Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer
by: Linda Leung, et al.
Published: (2012-07-01)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
by: Priya Sriskandarajah, et al.
Published: (2020-03-01)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors∗
by: Dipesh Uprety, MBBS, et al.
Published: (2020-03-01)

Targeting the EPHA2 receptor tyrosine kinase in KRAS and EGFR mutant lung cancer
by: Amato, Katherine Renee
Published: (2015)

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
by: Chen Gang, et al.
Published: (2012-03-01)

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
by: Yu-Mu Chen, et al.
Published: (2015-01-01)

Expression of Epidermal Growth Factor Receptor (EGFR) in Lung Adenocarcinoma
by: Kuo-Jung Lan, et al.
Published: (2012)

Genotyping of epidermal growth factor receptor by capillary electrophoresis and its application in pharmacogenomics of lung cancer therapy
by: Kun-Hsien Chao, et al.
Published: (2010)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma
by: You-Cai Zhu, et al.
Published: (2019-12-01)

Molecular Mechanism of Erlotinib Resistance in Epidermal Growth Factor Receptor  Mutant Non-small cell Lung Cancer Cell Line H1650
by: Ruili HAN, et al.
Published: (2012-12-01)

Cannot write session to /tmp/vufind_sessions/sess_2b7jjv7sffgaj4aakdnsghk283